Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
HARVARD BIOSCIENCE INC (HBIO)
|
Add to portfolio |
|
|
|
| Price: |
$6.91
| | Metrics |
| OS: |
42.7
|
M
| |
|
|
| Market cap: |
$295
|
M
| |
|
|
|
Net debt:
|
$37.1
|
M
| |
4.2
|
x Debt/EBITDA
|
|
EV:
|
$332
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$8.8
|
M
| |
37.5
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 113.3 | 118.9 | 102.1 | 116.2 | 120.8 | 77.4 | 104.5 | 108.7 |
| Revenue growth | -4.7% | 16.5% | -12.1% | -3.8% | 56.0% | -25.9% | -3.8% | 0.0% |
| Cost of goods sold | 52.5 | 51.3 | 44.1 | 51.9 | 57.6 | 38.2 | 56.1 | 59.9 |
| Gross profit | 60.8 | 67.7 | 58.0 | 64.3 | 63.2 | 39.2 | 48.4 | 48.7 |
| Gross margin | 53.7% | 56.9% | 56.8% | 55.4% | 52.3% | 50.6% | 46.3% | 44.8% |
| Sales and marketing | 25.0 | 24.6 | 19.9 | 23.3 | 24.4 | 15.1 | 20.5 | 20.6 |
| Research and development | 12.3 | 10.8 | 8.7 | 10.7 | 11.0 | 5.6 | 5.4 | 6.4 |
| General and administrative | 24.5 | 24.3 | 23.5 | 22.8 | 21.4 | 17.5 | 21.0 | 19.8 |
| EBITA | 12.8 | 3.8 | 5.9 | 7.6 | 6.4 | 1.8 | 1.6 | 1.9 |
| EBITA margin | 11.3% | 3.2% | 5.8% | 6.5% | 5.3% | 2.3% | 1.5% | 1.7% |
| Amortization of intangibles | 6.1 | 5.8 | 5.7 | 5.7 | 5.4 | 2.4 | 2.7 | 2.8 |
| EBIT | 6.7 | -2.1 | 0.2 | 1.8 | 1.0 | -0.6 | -1.1 | -0.9 |
| EBIT margin | 5.9% | -1.7% | 0.2% | 1.6% | 0.8% | -0.8% | -1.1% | -0.9% |
| Pre-tax income | -9.2 | -0.1 | -7.3 | -5.5 | -8.0 | -2.6 | -3.1 | -3.6 |
| Income taxes | 0.3 | 0.1 | 0.5 | -0.8 | -3.7 | -0.6 | 1.2 | 15.4 |
| Tax rate | | | | 14.8% | 46.1% | 23.1% | | |
| Earnings from continuing ops | -9.5 | -0.3 | -7.8 | -4.7 | -4.3 | -2.0 | -4.3 | -19.0 |
| Earnings from discontinued ops | | | | | 1.4 | 1.2 | | |
| Net income | -9.5 | -0.3 | -7.8 | -4.7 | -2.9 | -0.9 | -4.3 | -19.0 |
| Net margin | -8.4% | -0.2% | -7.6% | -4.0% | -2.4% | -1.1% | -4.1% | -17.5% |
| |
| Diluted EPS | ($0.23) | ($0.01) | ($0.20) | ($0.12) | ($0.12) | ($0.06) | ($0.13) | ($0.57) |
| Shares outstanding (diluted) | 41.4 | 40.3 | 38.6 | 37.8 | 36.5 | 34.8 | 34.2 | 33.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|